Erlotinib
roche
discussed our study ( pd-9) .erlotinib in addition to bsc improves mos by 2.07 months in unresectable/metastatic gbc patients unfit for chemo and should be the new standard.
#wcgic2022 grateful to my mentor prof. .thanks dr. 
Assistant Professor, Medical Oncology 
National Cancer institute-AIIMS 
D.M.(Med Onco) -AIIMS,New delhi